Halozyme Therapeutics | HALO - Loan Capital

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $800.07M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Baxter International USD 9.49B 80M Jun/2025
Cytokinetics USD 158.75M 554.3M Sep/2025
DBV Technologies USD 0 0 Mar/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Halozyme Therapeutics USD 800.07M 709.03M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
MannKind USD 303.65M 72.94M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
United Therapeutics USD 100M 100M Jun/2024